Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24809836 | 0.91 | USP2 (0.41) | USP2SMN1; SMN2TACR1NR1H2 | |
| SCHEMBL23536071 | 0.86 | USP2 (0.45) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL2349423 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL321594 | 0.81 | USP2 (0.49) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL1880398 | 0.80 | USP2 (0.51) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL1709866 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL2706445 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL25933667 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL23070921 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2TACR1NR1H2HPGD | |
| SCHEMBL605572 | 0.78 | USP2 (0.49) | USP2SMN1; SMN2NR1H2HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4549438-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-117304183-A | Five-membered and six-membered nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF2C | USP2 1987/4885SMN1; SMN2 81/4885TACR1 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.